Restech appointed CJM as the UK Exclusive Distributor for the Restech Dx-pH Measurement System which collects valuable information about patients’ acid reflux patterns and helps Physicians to accurately diagnose and treat reflux symptoms.
The addition of Restech pH Monitoring System, which measures acid reflux every 0.5 second in patient’s airway, compliments the existing CJ Medical product portfolio including the non-surgical Stretta® treatment for Gastro-Oesophageal Reflux Disease (GORD).
Jack Robb-Eadie, Sales Director, CJ Medical commented:
“The Restech pH system is the only minimally invasive, outpatient test which offers an effective and reliable solution to assess reflux patterns and its severity in patients. It does not require anaesthesia, insertion deep into the oesophagus or any additional placement procedures. Restech will compliment the Stretta procedure and strengthens the product offering to our UK customers.”
Restech pH sensor is unique in its ability to accurately function anywhere in the aerodigestive tract (from the oesophagus to the nasopharynx) reporting precise values of both liquid and aerosol (vapor) from pH 1–10.
The innovative Restech pH Monitoring System was recently presented alongside Stretta® Therapy at the British Society of Gastroenterology 2018 Conference (4th -7th June), Liverpool and was well-received by the Gastroenterology Group.
About CJ Medical
Specialising in surgical and medical devices, CJ Medical is committed to facilitating and promoting innovative technologies supported by professional education. Technologies represented by CJ Medical are used by Physicians in complex surgical procedures to reduce inpatient stay, improve quality of life and healthcare outcomes for patients and hospitals. CJ Medical is the UK Exclusive Distributor of Stretta®, Restech Dx-pH Monitoring System and Secca®.
About Restech Dx-pH Monitoring System
The Restech Dx–pH Measurement System is a revolutionary system that comfortably measures pH in the airway. Gastric reflux in the upper airway or laryngopharyngeal reflux, commonly takes a gaseous form that cannot be measured using conventional technology. The miniaturised pH sensor at the tip of the Dx–pH Probe is unique in its ability to measure pH in a non-liquid environment, such as the pharynx. By monitoring the pH levels in the pharynx, the Dx–System enables Physicians to confirm or deny the presence of laryngopharyngeal reflux and evaluate it as a possible contributor to their patients’ symptoms.
About Stretta® Therapy
The Stretta® procedure is a safe and effective treatment option for patients who suffer with Gastro-Oesophageal Reflux Disease (GORD) and wish to consider an alternative to medication or surgery for acid reflux. The innovative Stretta® system delivers low power, low temperature radiofrequency (RF) energy to the Lower Oesophageal Sphincter (LOS) muscle and gastric cardia, which remodels the tissue, resulting in improvement barrier function and fewer random relaxations that cause GORD symptoms. Stretta® Therapy has been widely studied with the recent 15-year data concluding Stretta safe and effective.